文献速递消化系统肿瘤

PD-L1与VEGF联合阻断在晚期恶性腹膜间皮瘤中的疗效、安全性及生物标志物分析

Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
PubMed 文献 · Cancer Discov · 2021-07-14

本研究在20例经铂类-培美曲塞化疗后进展或不耐受的晚期不可切除恶性腹膜间皮瘤患者中评估atezolizumab联合贝伐珠单抗的疗效与安全性。独立影像学评估的确认客观缓解率为40%(8/20;95%CI 19.1-64.0),中位缓解持续时间12.8个月,1年无进展生存率和总生存率分别为61%和85%。基线上皮-间质转化基因表达与治疗抵抗/应答相关(r=0.80;P=0.0010)。

要点

  • AtezoBev在经治晚期MPeM中确认ORR达40%,中位缓解持续时间12.8个月。
  • 1年PFS率61%、OS率85%,疗效不受低TMB和PD-L1表达状态影响。
  • 基线EMT基因表达与治疗抵抗/应答相关(r=0.80;P=0.0010)。

核心结论

  • AtezoBev在经铂类-培美曲塞化疗后进展或不耐受的晚期不可切除MPeM患者中显示出有前景且持久的疗效和可接受的安全性。

研究设计与样本

  • 在20例晚期不可切除且对先前铂类-培美曲塞化疗进展或不耐受的MPeM患者中评估AtezoBev的疗效与安全性。
  • 主要终点为独立影像学审查按RECISTv1.1评估的确认客观缓解率。

主要发现

  • 确认客观缓解率为40%(8/20;95%CI 19.1-64.0),中位缓解持续时间12.8个月。
  • 6例(75%)缓解持续时间超过10个月。
  • 1年无进展生存率为61%(95%CI 35-80),1年总生存率为85%(95%CI 60-95)。
  • 缓解发生于低肿瘤突变负荷和PD-L1表达状态下。
  • 基线上皮-间质转化基因表达与治疗抵抗/应答相关(r=0.80;P=0.0010)。

临床怎么用

  • 对于经铂类-培美曲塞化疗后进展或不耐受的晚期不可切除MPeM患者,AtezoBev可作为有前景的治疗选择。
  • 基线EMT基因表达可能有助于识别治疗抵抗/应答,但需进一步验证。

局限性

  • 样本量小(20例),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and safety of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade (AtezoBev) was assessed in 20 patients with advanced and unresectable MPeM with progression or intolerance to prior platinum-pemetrexed chemotherapy. The primary endpoint of confirmed objective response rate per RECISTv1.1 by independent radiology review was 40% [8/20; 95% confidence interval (CI), 19.1-64.0] with median response duration of 12.8 months. Six (75%) responses lasted for >10 months. Progression-free and overall survival at one year were 61% (95% CI, 35-80) and 85% (95% CI, 60-95), respectively. Responses occurred notwithstanding low tumor mutation burden and PD-L1 expression status. Baseline epithelial-mesenchymal transition gene expression correlated with therapeutic resistance/response (r = 0.80; P = 0.0010). AtezoBev showed promising and durable efficacy in patients with advanced MPeM with an acceptable safety profile, and these results address a grave unmet need for this orphan disease. SIGNIFICANCE: Efficacy of atezolizumab and bevacizumab vis-à-vis response rates and survival in advanced peritoneal mesothelioma previously treated with chemotherapy surpassed outcomes expected with conventional therapies. Biomarker analyses uncovered epithelial-mesenchymal transition phenotype as an important resistance mechanism and showcase the value and feasibility of performing translationally driven clinical trials in rare tumors.See related commentary by Aldea et al., p. 2674.This article is highlighted in the In This Issue feature, p. 2659.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Raghav K, Liu S, Overman MJ, et al. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021. PMID: 34261675. doi:10.1158/2159-8290.CD-21-0331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。